Urcosimod (OK-101)

About OKYO Pharma

OKYO Pharma is a UK-based, NASDAQ-listed biotech focused on developing novel treatments for ocular surface diseases, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). Its core achievement is pioneering the clinical path for NCP, having received the first-ever FDA IND clearance to evaluate a drug specifically for this condition. The company's strategy centers on its lead asset, Urcosimod, a first-in-class chemerin receptor agonist designed using its MAP technology to combat rapid ocular washout. OKYO aims to address multi-billion dollar markets with high unmet need through a targeted, platform-based approach.

About OKYO Pharma

OKYO Pharma is a UK-based, NASDAQ-listed biotech focused on developing novel treatments for ocular surface diseases, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). Its core achievement is pioneering the clinical path for NCP, having received the first-ever FDA IND clearance to evaluate a drug specifically for this condition. The company's strategy centers on its lead asset, Urcosimod, a first-in-class chemerin receptor agonist designed using its MAP technology to combat rapid ocular washout. OKYO aims to address multi-billion dollar markets with high unmet need through a targeted, platform-based approach.

Therapeutic Areas